Erythropoietin Stimulating Agents Market: By Product Type, By Application, By Distribution Channel, and Region Forecast 2019-2030
Erythropoietin Stimulating Agents Market size was valued at US$ 10.869 billion in 2023 and is expected to reach US$ 15.909 billion by 2030, at a CAGR of 8.6% during the forecast period 2024-2030. Erythropoietin is a hormone produced by kidney that enables stimulate production of RBC. Erythropoietin stimulating agents are the drugs used to stimulate the bone marrow to enhance the production of red blood cells. The drugs are commonly used in the treatment of anemia due to end stage renal disease (ESRD), major surgeries, chemotherapy, and HIV/AIDS leads to decrease the need of blood transfusion. Erythropoiesis is the name given to the process of red blood cell production. Erythropoiesis is a process that occurs in the bone marrow.
Erythropoiesis-stimulating agents are substances that promote the production of red blood cells. These are recombinant versions of the hormone erythropoietin, which is produced naturally by the kidneys and is responsible for promoting red blood cell formation in the bone marrow. For the treatment of anaemia, erythropoiesis-stimulating drugs are indicated. Hemoglobin is a protein found in red blood cells that transports oxygen throughout the body. Anemia occurs when the body does not obtain enough oxygen due to a low number of red blood cells.
Study Period
2024-2030Base Year
2023CAGR
8.6%Largest Market
Asia-PacificFastest Growing Market
Europe
The global market for erythropoiesis-stimulating drugs is growing due to the rising frequency of anaemia cases around the world. Furthermore, increased knowledge of erythropoiesis-stimulating agent therapy is fueling market expansion. Because of the expanding prevalence of chronic kidney disease and cancer, as well as the growing desire for less expensive erythropoietin medications, the demand for erythropoiesis-stimulating substances is fast increasing. Researchers and pharmaceutical companies are working to produce new erythropoietin medicines.
However, strict regulatory criteria and side effects associated with erythropoiesis-stimulating drugs, such as hypersensitivity, hypertension, seizures, or convulsions, are limiting market expansion. Rise in prevalence of anemia, ESRD, HIV, and cancer around the globe is witnessed to increased demand for global erythropoietin stimulating agents market. Moreover, rise in R&D for innovation of newer drugs, entry of bio-similar and generics into market due to expiration of patents are expected to increase in the adoption of low-cost drugs in developing countries, and rise in awareness about the benefits erythropoietin drugs are anticipated to propel the market over the forecast period. However, stringent regulations for the product approval, adverse effects associated with drugs, and high cost of patented drugs are impede the growth of market.
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 10.869 billion |
|
Market Size in 2030 |
US$ 15.909 billion |
|
Market CAGR |
8.6% |
|
By Product Type |
|
|
By Application |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Erythropoietin Stimulating Agents Market size was valued at US$ 10.869 billion in 2023 and is expected to reach US$ 15.909 billion by 2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Apotex, Biocon, Biosiduss, CCM, Claris Lifesciences, India*, Emcure, India*, Hexal, Hospira, Intas Pharmaceuticals, Medice, Nanogen Biopharmaceuticals, Sun Pharma, Sandoz, STADA, Amgen
rising frequency of anaemia cases around the world
Europe is the fastest-growing for erythropoietin stimulating agents market
| 1.Executive Summary |
| 2.Global Erythropoietin Stimulating Agents Market Introduction |
| 2.1.Global Erythropoietin Stimulating Agents Market - Taxonomy |
| 2.2.Global Erythropoietin Stimulating Agents Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Application |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Erythropoietin Stimulating Agents Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Erythropoietin Stimulating Agents Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Erythropoietin Stimulating Agents Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Epoetin-Alfa |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Epoetin-Beta |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Epoetin-Delta |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Epoetin-Omega |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Darbepoetin-Alfa |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Erythropoietin Stimulating Agents Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oncology |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Renal Disorders |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Anemia |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Surgeries |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Erythropoietin Stimulating Agents Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Erythropoietin Stimulating Agents Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Erythropoietin Stimulating Agents Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Epoetin-Alfa |
| 9.1.2.Epoetin-Beta |
| 9.1.3.Epoetin-Delta |
| 9.1.4.Epoetin-Omega |
| 9.1.5.Darbepoetin-Alfa |
| 9.1.6.Others |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oncology |
| 9.2.2.Renal Disorders |
| 9.2.3.Anemia |
| 9.2.4.Surgeries |
| 9.2.5.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Erythropoietin Stimulating Agents Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Epoetin-Alfa |
| 10.1.2.Epoetin-Beta |
| 10.1.3.Epoetin-Delta |
| 10.1.4.Epoetin-Omega |
| 10.1.5.Darbepoetin-Alfa |
| 10.1.6.Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oncology |
| 10.2.2.Renal Disorders |
| 10.2.3.Anemia |
| 10.2.4.Surgeries |
| 10.2.5.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Erythropoietin Stimulating Agents Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Epoetin-Alfa |
| 11.1.2.Epoetin-Beta |
| 11.1.3.Epoetin-Delta |
| 11.1.4.Epoetin-Omega |
| 11.1.5.Darbepoetin-Alfa |
| 11.1.6.Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oncology |
| 11.2.2.Renal Disorders |
| 11.2.3.Anemia |
| 11.2.4.Surgeries |
| 11.2.5.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Erythropoietin Stimulating Agents Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Epoetin-Alfa |
| 12.1.2.Epoetin-Beta |
| 12.1.3.Epoetin-Delta |
| 12.1.4.Epoetin-Omega |
| 12.1.5.Darbepoetin-Alfa |
| 12.1.6.Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oncology |
| 12.2.2.Renal Disorders |
| 12.2.3.Anemia |
| 12.2.4.Surgeries |
| 12.2.5.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Erythropoietin Stimulating Agents Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Epoetin-Alfa |
| 13.1.2.Epoetin-Beta |
| 13.1.3.Epoetin-Delta |
| 13.1.4.Epoetin-Omega |
| 13.1.5.Darbepoetin-Alfa |
| 13.1.6.Others |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oncology |
| 13.2.2.Renal Disorders |
| 13.2.3.Anemia |
| 13.2.4.Surgeries |
| 13.2.5.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Apotex |
| 14.2.2.Biocon |
| 14.2.3.Biosiduss |
| 14.2.4.CCM |
| 14.2.5.Hospira |
| 14.2.6.Intas Pharmaceuticals |
| 14.2.7.Medice |
| 14.2.8.Nanogen Biopharmaceuticals |
| 14.2.9.La Renon Healthcare Pvt Ltd |
| 14.2.10.3Emcure Pharmaceuticals Ltd |
| 14.2.11.Zuventus Healthcare Ltd |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
